ArticleCancers2020
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
Donatella Romaniello et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
41 papers cite it
this papercites it